Aclaris Therapeutics, Inc. (ACRS)

5.50 +0.10 (+1.85%) USD  |  NASDAQ  |  Sep 18, 16:00
5.51 +0.01 (+0.18%) After-Hours: 07:52
More

Aclaris Therapeutics Total Long Term Debt (Quarterly) : 1.262M for June 30, 2026

Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for ACRS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 1.262M
March 31, 2026 1.416M
December 31, 2025 1.565M
September 30, 2025 1.711M
June 30, 2025 1.851M
March 31, 2025 1.986M
December 31, 2024 2.117M
September 30, 2024 2.245M
June 30, 2024 2.367M
March 31, 2024 2.971M
December 31, 2023 3.074M
September 30, 2023 1.834M
June 30, 2023 1.903M
March 31, 2023 1.97M
December 31, 2022 1.57M
September 30, 2022 1.617M
June 30, 2022 1.82M
March 31, 2022 2.015M
December 31, 2021 2.201M
September 30, 2021 2.383M
June 30, 2021 13.29M
March 31, 2021 13.42M
Date Value
December 31, 2020 13.55M
September 30, 2020 13.67M
June 30, 2020 13.87M
March 31, 2020 14.05M
December 31, 2019 3.68M
September 30, 2019 33.91M
June 30, 2019 35.39M
March 31, 2019 33.56M
December 31, 2018 29.91M
September 30, 2018 0.591M
June 30, 2018 0.552M
March 31, 2018 0.142M
December 31, 2017 0.00
September 30, 2017 0.00
June 30, 2017 0.00
March 31, 2017 0.00
December 31, 2016 0.00
September 30, 2016 0.00
June 30, 2016 0.00
March 31, 2016 0.00
December 31, 2015 0.00
September 30, 2015 0.00

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Corcept Therapeutics, Inc. 7.504M
Nektar Therapeutics 113.23M
Xeris Biopharma Holdings, Inc. 283.13M
Alumis, Inc. 31.60M
ANI Pharmaceuticals, Inc. 610.49M